Curaleaf Holdings (CURLF) Liabilities from Discontinued Operations (2020 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Liabilities from Discontinued Operations of 7073000.0 for Q4 2025, down 20.57% year-on-year from 8905000.0 in Q4 2024, and down 20.57% on a QoQ basis from 8905000.0 in Q4 2024.
Curaleaf Holdings (CURLF) Liabilities from Discontinued Operations (2020 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Liabilities from Discontinued Operations for 6 consecutive years, with 7073000.0 the latest figure, recorded in Q4 2025.
- Quarterly Liabilities from Discontinued Operations fell 20.57% year-over-year to 7073000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 7073000.0 (down 20.57% YoY) and the FY2025 annual result came in at 7073000.0, down 20.57% from the prior year.
- Liabilities from Discontinued Operations fell to 7073000.0 in Q4 2025 per CURLF's latest filing, from 8905000.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for CURLF reached as high as 23045000000.0 in Q1 2022 and fell as low as 1067000.0 in Q3 2024.
- A 5-year average of 1549350066.67 and a median of 12775000.0 in 2021 frame the typical range for Liabilities from Discontinued Operations.
- Annual changes were most pronounced in 2022 — Liabilities from Discontinued Operations jumped 180291.39% — and 2024, when it plunged 95.67%.
- Year by year, Liabilities from Discontinued Operations stood at 18581000.0 in 2021, then surged by 91.3% to 35545000.0 in 2022, then slumped by 74.19% to 9173000.0 in 2023, then slipped by 2.92% to 8905000.0 in 2024, then declined by 20.57% to 7073000.0 in 2025.
- According to Business Quant data, Liabilities from Discontinued Operations over the past three periods registered 7073000.0, 8905000.0, and 1067000.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.07 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Dec 31, 2024 | 8.91 Mn |
| Dec 31, 2024 | 8.91 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 3.00 Mn |
| Dec 31, 2023 | 9.17 Mn |
| Dec 31, 2023 | 9.17 Mn |
| Sep 30, 2023 | 24.62 Mn |
| Sep 30, 2023 | 24.62 Mn |
| Jun 30, 2023 | 10.51 Mn |
| Jun 30, 2023 | 10.51 Mn |
| Dec 31, 2022 | 35.55 Mn |
| Dec 31, 2022 | 35.55 Mn |
| Sep 30, 2022 | 15.83 Mn |
| Sep 30, 2022 | 15.83 Mn |
| Jun 30, 2022 | 18.85 Mn |
| Jun 30, 2022 | 18.85 Mn |